Analyst Upgrades: Valeant Pharmaceuticals, Silver Wheaton, AT&T

Analysts upwardly revised their ratings on Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Silver Wheaton Corp. (USA) (NYSE:SLW), and AT&T Inc. (NYSE:T)

Oct 27, 2015 at 10:03 AM
facebook X logo linkedin


Analysts are weighing in on biotech Valeant Pharmaceuticals Intl Inc (NYSE:VRX), mining firm Silver Wheaton Corp. (USA) (NYSE:SLW), and telecom titan AT&T Inc. (NYSE:T). Here's a quick roundup of today's bullish brokerage notes on VRX, SLW, and T.

  • After giving up more ground on Monday, VRX is attempting to pare some of its recent losses today, adding 0.5% to $110.54. Apparently, an upgrade to "buy" at Mizuho is outweighing price-target cuts from three other brokerage firms. Elsewhere, Turing Pharmaceuticals CEO Martin Shkreli said he has unwound his long position on the shares, which were off over 23% year-to-date coming into today -- with most of the losses triggered by Citron Research's short-seller report. What's more, activist investor Bill Ackman said he will be discussing his investment in the company during a conference call this Friday. Despite Valeant Pharmaceuticals Intl Inc's dramatic struggles, it still has fans on Wall Street. Eight of 12 covering analysts say the equity is a "buy" or better, with not a single firm handing out a "sell" rating.
  • Barclays initiated coverage on SLW with an "overweight" opinion and $18 price target this morning. The stock is 0.7% higher out of the gate at $14.38, but remains more than 29% lower over the past 12 months. At least one group is betting on more troubles ahead for Silver Wheaton Corp., which is slated to release earnings one week from tonight. Specifically, short interest on the security jumped by over 40% during the past two reporting periods. 
  • is off 0.2% at $33.60 this morning, failing to take advantage of a price-target increase to $41 from $40 at Cowen and Company. On the charts, the telecom giant is fighting to overcome its 200-day moving average, a level that served as support during the summer months, but may be switching roles to act as resistance. Short-term speculators don't seem to be betting on AT&T Inc. to break out, though, even after the company's recent earnings report came in better than expected. The stock's Schaeffer's put/call open interest ratio (SOIR) of 1.24 is only 6 percentage points from an annual high. This means that traders targeting options that expire within three months are much more put-skewed than what's normally seen. 
Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI